BROOKS

Brooks Laboratories Share Price

 

 

Start SIP in BROOKS

Start SIP

Performance

  • Low
  • ₹96
  • High
  • ₹103
  • 52 Week Low
  • ₹95
  • 52 Week High
  • ₹199
  • Open Price₹98
  • Previous Close₹99
  • Volume28,875

Investment Returns

  • Over 1 Month -10.81%
  • Over 3 Month -35.24%
  • Over 6 Month -29.38%
  • Over 1 Year -28.07%

Smart Investing Starts Here Start SIP with Brooks Laboratories for Steady Growth!

Invest Now

Brooks Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 25
  • PEG Ratio
  • 0.2
  • Market Cap Cr
  • 288
  • P/B Ratio
  • Average True Range
  • 5.61
  • EPS
  • 4.74
  • Dividend Yield
  • 0
  • MACD Signal
  • -4.8
  • RSI
  • 36.5
  • MFI
  • 42.96

Brooks Laboratories Financials

Brooks Laboratories Technicals

EMA & SMA

Current Price
₹97.82
-0.68 (-0.69%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹103.37
  • 50 Day
  • ₹113.61
  • 100 Day
  • ₹123.61
  • 200 Day
  • ₹129.57

Resistance and Support

98.89 Pivot Speed
  • R3 107.87
  • R2 105.23
  • R1 101.53
  • S1 95.19
  • S2 92.55
  • S3 88.85

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Brooks Laboratories has an operating revenue of Rs. 110.73 Cr. on a trailing 12-month basis. An annual revenue growth of 4% is not great, Pre-tax margin of 4% needs improvement, ROE of -10% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 66 which is a FAIR score but needs to improve its earnings, a RS Rating of 13 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D which indicates heavy supply, Group Rank of 41 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Brooks Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-14 Quarterly Results
2025-08-13 Quarterly Results
2025-05-28 Audited Results
2025-02-13 Quarterly Results
2024-12-11 To consider Fund Raising & Others Inter-alia, to consider and approve 1. Proposal for Raising Funds through the issuance of securities (Equity Shares) by way of a preferential issue. 2. To approve the EGM. 3. Other business matters. issue of equity shares of Rs. 10/- in the ratio of 1:16 @ premium of Rs. 65/-.

Brooks Laboratories F&O

Brooks Laboratories Shareholding Pattern

52.62%
9.9%
0%
0.01%
0%
31.7%
5.77%

Brooks Laboratories FAQs

Brooks Laboratories share price is ₹97 As on 07 December, 2025 | 10:41

The Market Cap of Brooks Laboratories is ₹288.2 Cr As on 07 December, 2025 | 10:41

The P/E ratio of Brooks Laboratories is 25 As on 07 December, 2025 | 10:41

The PB ratio of Brooks Laboratories is 4.6 As on 07 December, 2025 | 10:41

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23